Published in Acta Endocrinol (Copenh) on May 01, 1985
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate (1983) 2.29
Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim. Cell Death Differ (2008) 1.60
Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives. Contraception (1989) 1.48
[Risk of thrombosis with oral contraceptives]. Zentralbl Gynakol (1996) 1.40
Observation of an antimatter hypernucleus. Science (2010) 1.38
Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil Steril (1978) 1.24
Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception (2003) 1.13
Elliptic flow of charged particles in Pb-Pb collisions at sqrt[S(NN)] = 2.76 TeV. Phys Rev Lett (2010) 1.12
Particle-yield modification in jetlike azimuthal dihadron correlations in Pb-Pb collisions at √s(NN)=2.76 TeV. Phys Rev Lett (2012) 1.11
Transverse momentum distribution and nuclear modification factor of charged particles in p+Pb collisions at sqrt[s(NN)] = 5.02 TeV. Phys Rev Lett (2013) 1.08
Higher harmonic anisotropic flow measurements of charged particles in Pb-Pb collisions at sqrt(s(NN)) = 2.76 TeV. Phys Rev Lett (2011) 1.05
Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation (2001) 0.99
Production of muons from heavy flavor decays at forward rapidity in pp and Pb-Pb collisions at sqrt[s(NN)]=2.76 TeV. Phys Rev Lett (2012) 0.98
Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception (1995) 0.98
Strange baryon resonance production in sqrt s NN=200 GeV p+p and Au+Au collisions. Phys Rev Lett (2006) 0.96
Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium. J Pharm Sci (2000) 0.95
Transverse-momentum and collision-energy dependence of high-pT hadron suppression in Au+Au collisions at ultrarelativistic energies. Phys Rev Lett (2003) 0.93
Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception (2004) 0.93
Impact of congenital or experimental hypogonadotrophism on the radiation sensitivity of the mouse ovary. Hum Reprod (1997) 0.93
Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther (2011) 0.93
Evidence from d+Au measurements for final-state suppression of high-p(T) hadrons in Au+Au collisions at RHIC. Phys Rev Lett (2003) 0.92
Clinical applications of LHRH and its analogues. Clin Endocrinol (Oxf) (1983) 0.90
Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings. Contraception (1990) 0.87
Mammary derived growth inhibitor is not a distinct protein but a mix of heart-type and adipocyte-type fatty acid-binding protein. J Biol Chem (1996) 0.87
Treatment of cryptorchidism with pernasal gonadotropin-releasing hormone therapy. Fertil Steril (1978) 0.87
Evidence for an exotic S= -2, Q= -2 baryon resonance in proton-proton collisions at the CERN SPS. Phys Rev Lett (2004) 0.86
Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. Exp Clin Endocrinol Diabetes (2007) 0.86
Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception (2003) 0.85
A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraception (1998) 0.85
Antibody production against an agonist analogue of luteinizing hormone-releasing hormone: evaluation of immunochemical and physiological consequences. Acta Endocrinol (Copenh) (1983) 0.84
Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism. Am J Obstet Gynecol (1990) 0.84
Effect of near-infrared light on the S2-state of the manganese complex of photosystem II from Synechococcus elongatus. Biochemistry (1998) 0.84
Effect of four oral contraceptives on hemostatic parameters. Contraception (2004) 0.84
The adjuvant effect of bacitracin on nasal absorption of gonadorelin and buserelin in rats. Pharm Res (1988) 0.84
Specific binding of benzodiazepines to human breast cancer cell lines. Life Sci (1999) 0.83
New aspects of the physiological significance of LRH receptors of pituitary plasma membranes. Acta Endocrinol (Copenh) (1981) 0.83
Azimuthal charged-particle correlations and possible local strong parity violation. Phys Rev Lett (2009) 0.83
Suppression of follicular maturation by infusion of a luteinizing hormone-releasing hormone agonist starting during the late luteal phase in the stumptailed macaque monkey. J Clin Endocrinol Metab (1985) 0.82
Cellular binding proteins for vitamin A in colorectal adenocarcinoma of rat. Cancer Res (1978) 0.82
J/ψ elliptic flow in Pb-Pb collisions at √(s(NN))=2.76 TeV. Phys Rev Lett (2013) 0.82
Studies with fragments of a highly active analogue of luteinizing hormone releasing hormone. J Endocrinol (1979) 0.81
Inactivation of luteinizing hormone releasing hormone by rat hypothalamic L-cystine arylamidase. Acta Endocrinol (Copenh) (1975) 0.81
Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol (1987) 0.81
GRF elevates cytosolic free calcium concentration in rat anterior pituitary cells. Am J Physiol (1987) 0.81
Cell cycle-related expression and ligand binding of peripheral benzodiazepine receptor in human breast cancer cell lines. Eur J Cancer (2000) 0.81
A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic serum parameters: II. Effects upon thyroid function, gastrin, STH, and glucose tolerance. Contraception (1985) 0.81
Reduced glutathione and S-acetylglutathione as selective apoptosis-inducing agents in cancer therapy. Cancer Lett (1996) 0.81
Suppression of pituitary and testicular function in normal men by constant gonadotropin-releasing hormone agonist infusion. J Clin Endocrinol Metab (1984) 0.81
Pseudorapidity density of charged particles in p+Pb collisions at √(s(NN))=5.02 TeV. Phys Rev Lett (2013) 0.81
Stimulation of release of LH by synthetic LH-RF in vivo. I. A comparative study of natural and synthetic hormones. Endocrinology (1972) 0.80
J/ψ polarization in pp collisions at √s=7 TeV. Phys Rev Lett (2012) 0.80
[Biosynthesis of folic acid- and NAD-analogs]. Hoppe Seylers Z Physiol Chem (1967) 0.80
Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril (1989) 0.80
Pion, kaon, and proton production in central Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 0.80
IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy. Climacteric (2005) 0.80
An implant of a gonadotropin releasing hormone agonist (buserelin) which suppresses ovarian function in the macaque for 3-5 months. Acta Endocrinol (Copenh) (1987) 0.80
Charge separation relative to the reaction plane in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2013) 0.80
Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. Urol Res (1989) 0.80
The first clinical use of depot buserelin for advanced prostatic carcinoma. Cancer Chemother Pharmacol (1986) 0.79
Effect of two oral contraceptives containing 30 micrograms ethinylestradiol and 75 micrograms gestodene or 150 micrograms desogestrel upon various hormonal parameters. Contraception (1988) 0.79
A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer. Cancer Chemother Pharmacol (1989) 0.79
[(8-Homoargine) (luteinizing hormone releasing hormone) (author's transl)]. Hoppe Seylers Z Physiol Chem (1974) 0.79
Properties of an antiserum against Streptomyces hydrogenans 20beta-hydroxysteroid dehydrogenase. Z Naturforsch C (1976) 0.79
Failure of high-dose sustained release luteinizing hormone releasing hormone agonist (buserelin) plus oral testosterone to suppress male fertility. Clin Endocrinol (Oxf) (1985) 0.79
The relation between pharmacokinetics and endocrine effects of buserelin implants in patients with mastalgia. Clin Endocrinol (Oxf) (1991) 0.79
Relation of cell proliferation to expression of peripheral benzodiazepine receptors in human breast cancer cell lines. Biochem Pharmacol (2000) 0.79
The regulation of LHRH action at the pituitary and gonadal receptor level: a review. Psychoneuroendocrinology (1983) 0.79
Effect of human growth hormone-releasing hormone on the release of dynorphin-like immunoreactivity, luteinizing hormone, and follicle-stimulating hormone from rat adenohypophysis in vitro. Endocrinology (1987) 0.79
Pathways of degradation of buserelin by rat kidney membrane. J Pharmacol Exp Ther (1995) 0.79
Direct observation of dijets in central Au+Au collisions at sqrt[sNN]=200 GeV. Phys Rev Lett (2006) 0.79
Inhibitory control of the pituitary LH secretion by LH-RH in male rats. Horm Res (1979) 0.79
Distributions of charged hadrons associated with high transverse momentum particles in pp and Au+Au collisions at sqrt[sNN]=200 GeV. Phys Rev Lett (2005) 0.79
The different mechanisms for suppression of pituitary and testicular function. Med Biol (1986) 0.78
Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations. J Cancer Res Clin Oncol (1993) 0.78
Luteinizing hormone-releasing hormone (LH-RH) activity of some synthetic polypeptides. I. Fragments shorter than decapeptide. Biochem Biophys Res Commun (1972) 0.78
Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception (1998) 0.78
A randomized cross-over comparison of two low-dose oral contraceptives upon hormonal and metabolic parameters: I. Effects upon sexual hormone levels. Contraception (1985) 0.78
Stimulation of growth hormone release by anterior pituitary perfusion in the rat. Endocrinology (1972) 0.78
Three-monthly GnRH agonist (buserelin) for prostatic cancer. Br J Urol (1990) 0.78
The effect of sex steroids and hormonal contraceptives upon thymus and spleen on intact female rats. Contraception (1983) 0.78
Gonadotrophin release by a highly active analogue of luteinizing hormone releasing hormone in rats immunized against luteinizing hormone releasing hormone. J Endocrinol (1977) 0.78
Prevention of follicular maturation in endometriosis by subcutaneous infusion of luteinizing hormone-releasing hormone agonist started in the luteal phase. Fertil Steril (1988) 0.77
Effects of combined oral contraceptive ethinylestradiol (30 microg) and dienogest (2 mg) on carbohydrate metabolism during 1 year of conventional or extended-cycle use. Horm Metab Res (2010) 0.77
Enzyme kinetic studies and inhibition by oligopeptides of LH-RH degradation in rat hypothalamus and pituitary. Neuroendocrinology (1979) 0.77
Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Maturitas (1995) 0.77
[Clear cell adenocarcinoma of the ovary (Saphir and Lackner) and so-called mesonephroma ovarii (Schiller) as combined tumors. Review of the literature and case report]. Arch Gynakol (1968) 0.77
Degradation of luteinizing hormone - releasing hormone and analogs by adenohypophyseal peptidases. Biochem Biophys Res Commun (1981) 0.77
Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. Horm Res (1991) 0.77
Lack of effect on the low density lipoprotein receptor in hamsters treated with 17 alpha-ethinyl estradiol. Biochim Biophys Acta (1994) 0.77
Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception (2002) 0.77
Open charm yields in d+Au collisions at squareroot[sNN]=200 GeV. Phys Rev Lett (2005) 0.76
S- and C-glycopeptide derivatives of an LH-RH agonist. Int J Pept Protein Res (1996) 0.76
Estrogen replacement therapy and Alzheimer's disease. Drugs Today (Barc) (1998) 0.76
Detection of an electron paramagnetic resonance signal in the S0 state of the manganese complex of photosystem II from Synechococcus elongatus. Biochemistry (1999) 0.76
[Effect of 2 low-dosage Gestodene or desogestrel containing ovulation inhibitors on sex hormones and lipid metabolism]. Geburtshilfe Frauenheilkd (1988) 0.76
Identified hadron compositions in p+p and Au+Au collisions at high transverse momenta at √S(NN)=200 GeV. Phys Rev Lett (2012) 0.76
Chronic treatment with LH-RH in golden hamsters. Acta Endocrinol (Copenh) (1978) 0.76